ClinicalTrials.gg
Status unknownNCT05132413Updated Nov 24, 2021

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

A Phase 3 interventional study of SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab and Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
561
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
19th of 223
561 · median 64
Started
2021
with 3 others
Phase 3
44 of 227
4 open now
Registered
205th of 227
by date

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by planned enrollment of the 223 interventional ones that give a count, is one of 4 that started in 2021, is one of 44 in phase 3, and was the 205th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after failure of TKIs

03

Conditions studied

  • Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

A subject must satisfy all of the following criteria to be considered for inclusion in the study:

  1. or cytologically confirmed advanced or non-squamous non-small cell lung cancer.
  2. Failed with prior EGFR-TKIs treatments.
  3. , as defined by v1.1
  4. The Eastern Cancer Cooperative Group () performance status of 0 or 1
  5. ≥ 3 months
  6. Adequate hematologic and end-organ function as defined in the protocol

Exclusion criteria

Exclusion Criteria:

-

A subject who meets any of the following criteria will be excluded from study entry:

  1. or cytologically confirmed mixed SCLC and NSCLC.
  2. Symptomatic, untreated or active central nervous system .
  3. Systemic therapy with agents within 2 weeks prior to initiation of study treatment
  4. With any active disease or history of autoimmune disease.
  5. Inadequately controlled hypertension.
  6. Tumour infiltration into the great vessels on imaging.
  7. History of haemoptysis ≥2.5ml per episode within 1 month prior to initiation of study treatment.
  8. Uncontrolled tumour-related pain.
  9. Patients with active or
  10. Severe infections within 4 weeks prior to initiation of study treatment. Active tuberculosis within one year prior to initiation of study treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
561 participants (estimated)

Study arms

  • Experimental
    treatment group

    Drug: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

  • Placebo comparator
    Placebo group 1

    Drug: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin

  • Placebo comparator
    Placebo group 2

    Drug: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

Interventions

  • DrugSHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

    Drug pages: SHR-1701 · Pemetrexed · Cisplatin · Carboplatin · Bevacizumab

    SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

  • DrugPlacebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin

    Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin

  • DrugPlacebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

    Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and immune-related adverse events (irAEs) as per NCI-CTC AE 5.0 (Stage I)

    Time frame: 2 years

  2. BIRC-assessed progression-free survival (PFS) as per RECIST v1.1(Stage II)

    Time frame: 2 years

Secondary outcomes

  1. Progression free survival (PFS)(Stage I)

    Time frame: 2 years

  2. Objective response rate (ORR)(Stage I)

    Time frame: 2 years

  3. Disease control rate (DCR) (Stage I)

    Time frame: 2 years

  4. Duration of response (DOR) (Stage I)

    Time frame: 2 years

  5. Overall survival (OS) (Stage I)

    Time frame: 2 years

  6. Progression free survival (PFS)(Stage II)

    Time frame: 2 years

  7. Objective response rate (ORR)(Stage II)

    Time frame: 2 years

  8. Disease control rate (DCR)(Stage II)

    Time frame: 2 years

  9. Duration of response (DOR) (Stage II)

    Time frame: 2 years

  10. Overall survival (OS) (Stage II)

    Time frame: 2 years

  11. Incidence and severity of adverse events (AEs), serious adverse events (Stage II)

    Time frame: 2 years

  12. (SAEs), and immune-related adverse events (irAEs) as per NCI-CTC AE 5.0(Stage II)

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2021; primary completion for Dec 2024, 36 months later.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 36 months is close to that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 24, 2021
StartEst.
Dec 30, 2021
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05132413
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Dec 30, 2021 (estimated)
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Nov 24, 2021

Study contacts

Yuanchao Wang
Contact
yuanchao.wang@hengrui.com
0518-81220278
You Li
Contact
you.li.yl1@hengrui.com
0518-81220278

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SHR-1701 · Pemetrexed · Cisplatin · Carboplatin · Bevacizumab

Start the discussion